We have previously shown that the small heat shock protein HSP27 inhibited apoptotic pathways triggered by a variety of stimuli in mammalian cells. The present study demonstrates that HSP27 overexpression decreases U937 human leukemic cell sensitivity to etoposide-induced cytotoxicity by preventing apoptosis. As observed for Bcl-2, HSP27 overexpression delays poly(ADP-ribose)polymerase cleavage and procaspase-3 activation. In contrast with Bcl-2, HSP27 overexpression does not prevent etoposide-induced cytochrome c release from the mitochondria. In a cell-free system, addition of cytochrome c and dATP to cytosolic extracts from untreated cells induces the proteolytic activation of procaspase-3 in both control and bcl-2-transfected U937 cells but fails to activate procaspase-3 in HSP27-overexpressing cells. Immunodepletion of HSP27 from cytosolic extracts increases cytochrome c/dATP-mediated activation of procaspase-3. Overexpression of HSP27 also prevents procaspase-9 activation. In the cell-free system, immunodepletion of HSP27 increases LEDH-AFC peptide cleavage activity triggered by cytochrome c/dATP treatment. We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATPtriggered activity of caspase-9, downstream of cytochrome c release.-Garrido, C., Bruey, J.-M., Fromentin, A., Hammann, A., Arrigo, A. P., Solary, E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB
mines the fate of damaged cells. Enzymes from the caspase family of proteases that are sensitive to the tetrapeptide DEVD play a central role in druginduced cell death (4, 5) , whereas the antiapoptotic protein Bcl-2 delays etoposide-induced apoptosis without modifying the formation and repair of DNA damage provoked by the drug (6) . Concerning the molecular ordering of this pathway, a picture has emerged in which Bcl-2 family proteins regulate the release of apoptogenic molecules such as cytochrome c, which activates cytosolic procaspases, and apoptosis-initiating factor, which triggers nuclear changes, from the mitochondria (7) (8) (9) (10) (11) (12) .
Among other molecules that can interfere with this cell death pathway (13, 14) is the small heat shock protein HSP27. Small heat shock proteins are overexpressed in response to environmental stresses (15) ; they vary in size from 15 to 30 kDa and share sequence homologies and biochemical properties such as phosphorylation and oligomerization (16) . These proteins may act as molecular chaperones, regulate actin cytoskeleton organization (17, 18) , and modulate redox parameters (19) . Their overexpression efficiently protects against cell death triggered by a variety of stimuli including hyperthermia (20) , oxidative stress (21, 22) , and several commonly used anticancer drugs (21, (23) (24) (25) . The small stress protein HSP27 is expressed in both normal and neoplastic human cells. We have demonstrated the ability of this protein to protect cells against staurosporine-, Fas/APO-1- (14) and cytotoxic drug-induced apoptosis (25) . We have also shown that HSP27 protein contributes to cancer cell tumorigenicity (26) .
In this work, we analyzed the mechanisms by which HSP27 modulates etoposide-induced apoptosis in U937 human leukemic cells. We show that HSP27 overexpression prevents the activation of procaspase-9 and the subsequent activation of procaspase-3 and cleavage of poly(ADP-ribose)poly-merase (PARP). In contrast to Bcl-2, HSP27 functions downstream of the mitochondrial release of cytochrome c.
MATERIALS AND METHODS

Cells, plasmids, transfection, and drug treatment
The human leukemic cell line, U937, was grown in suspension in RPMI 1640 medium (BioWhittaker, Fontenay-sousbois, France) supplemented with 10% (v/v) fetal bovine serum and 2 mM L-glutamine in a controlled atmosphere (37°C, 5% CO 2 ). The plasmids used for transfections were psvhsp27 containing the full-length human HSP27 cDNA, psvK3 as an insertless control, and pG-hygro containing the hygromicin-B resistance gene (27) . Cells were transfected by electroporation (250 V, 1,500 F) with 25 g of psvhsp27 or psvK3 and 2.5 g of pG-hygro, and selected 48 h later in hygromycin B-supplemented medium (Sigma-Aldrich, St. Quentin Fallavier, France). Expression of HSP27 in isolated clones was analyzed by Western blot. Cell growth analyses were performed by plating 10 5 cells in 35 mm tissue culture dishes on day 0, then counting the cells every 24 h by using a hemocytometer (four independent determinations for each time point). Etoposide (Sigma-Aldrich) stock solution was prepared in dimethyl sulfoxide (DMSO) and stored at Ϫ20°C for less than 1 month. The final concentration of DMSO in the culture medium never exceeded 0.1% (v/v), which was nontoxic to the cells.
In vivo fluorescent measurement of intracellular ROS
The fluorescent probe hydroethidine (Molecular Probe-Interchim, Montluçon, France), which is the NaBH 4 -reduced form of ethidium bromide, was used to measure the intracellular content of ROS in living cells (28) . Cells were washed twice with NaCl/Pi, pH 7.4 (PBS), and incubated for 10 min with 40 g/ml hydroethidine. The flow cytometry analysis was performed by using a FACScan flow cytometer (Becton Dickinson, Le Pont de Claix, France). Mean oxidized HE (ethidium bromide) fluorescence indices were calculated by dividing the mean EB fluorescence of each sample by that measured in wild-type U937 cells.
Western blot analysis
Whole cell lysates were prepared by lysing the cells in 2% sodium dodecyl sulfate (SDS), 137 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , and NaCl/P i (pH 7.4) at 68°C for 5 min. Protein concentration was measured in the supernatant by the use of the micro BCA protein assay (Pierce, Asnieres, France). Proteins were separated in a 8 -12% SDS-polyacrylamide gel and electroblotted to PVDF membranes (Bio-Rad, Ivry sur Seine, France). After blocking nonspecific binding sites with 5% nonfat milk in NaCl/Pi, pH 7.4, 0.1% Tween 20 (TPBS), blots were incubated with specific antibodies, washed in TPBS, incubated for 30 min at room temperature with horseradish peroxidase-conjugated goat antimouse or antirabbit antibodies ( Jackson ImmunoResearch Laboratories, West Grove, Pa.), and revealed following the ECL Western blotting analysis procedure (Amersham, Les Ullis, France). All the Western analyses were repeated three times. Antibodies used were the mouse monoclonal anti-human HSP27, HSP70, HSP90 (StressGen, Victoria, Canada), the rabbit polyclonal anti-human caspase-9, the mouse monoclonal antihuman cytochrome c, caspase-2, caspase-6, caspase-8 (PharMingen, San Diego, Calif.), the rabbit polyclonal anti human PARP (Boehringer Mannheim SA, Meylan, France), and procaspase-3 (kindly provided by Donald W. Nicholson, Merck-Frost Co, Toronto, Canada).
Drug cytotoxicity assay
U937 cells (10 4 ) were seeded in 96-well microculture plates for 24 h, then treated with increasing concentrations of etoposide. The number of surviving cells was measured after 96 h of drug exposure by the use of an MTT assay as described previously (29) .
Identification of apoptosis
Exposure of phosphatidylserine on the outer membrane leaflet was determined by the use of the annexin V-FITC kit (Bioproducts, Boehringer Ingelheim, Heidelberg). The percentages of apoptotic cells were calculated using a FACScan flow cytometer (Becton Dickinson). Identification of apoptotic cells was also performed by chromatin staining with 5 g/ml Hoechst 33342 for 30 min at 37°C. Cells with condensed chromatin were counted by using a Leitz microscope equipped with an epi-illuminator and appropriate filters (Leica, Bron, France). The percentages of apoptotic cells were determined from 300 cells counted in triplicate.
In vivo measurement of mitochondrial membrane potential
The cationic lipophilic fluorochrome 3,3Ј dihexyloxacarbocyanine (DiOC 6 , Sigma Chemical Co., St. Louis, Mo.) was used to measure the ⌬ m . Etoposide treated and untreated cells were washed in PBS and incubated at 37°C for 30 min with 0.1 M DiOC 6 . As a positive control, cells were exposed to 100 M carbonyl cyanide m-chlorophenylhydrazone (mCICCP, Sigma Chemical Co.). Results were recorded in FL1.
Cell fractionation
Nuclei-free, mitochondria-free cytosolic extracts were prepared as described (30) . Briefly, cells were washed in ice-cold PBS, pH 7.2, then in hypotonic extraction buffer (HEB: 50 mM PIPES, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride), and centrifuged. The pellet was resuspended in HEB, transferred to a 2 ml Dounce homogenizer and lysed. This cell lysate was centrifuged for 30 min at 16,000 ϫ g at 4°and the clarified supernatant was either tested immediately or stored in aliquots at Ϫ80°C. In some experiments, HSP27 from U937 cell-free extracts was immunoabsorbed using 0.1 g/ml anti-human HSP27 mAb (MedGene Science S.A., Pantin, France) and protein A-Sepharose (Pharmacia Biotech, Uppsala, Sweden). Mitochondrial and cytosolic (S100) fractions for cytochrome c release studies were prepared by resuspending the cells in ice-cold buffer A [250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 17 g/ml PMSF, 8 g/ml aprotinin, 2 g/ml leupeptin (pH 7.4)] before passing them through an ice-cold cylinder cell homogenizer. Unlysed cells and nuclei were pelleted via a 10 min, 750 ϫ g spin. The supernatant was spun at 10,000 ϫ g for 25 min. This pellet was resuspended in buffer A and contained the mitochondrial fraction. The supernatant was spun at 100,000 ϫ g for 1 h. The supernatant from this final centrifugation contained the cytosolic S100 fraction.
ApoAlert CPP32 Assay Kit (Clontech Laboratories Inc., Palo Alto, Calif.). One arbitrary unit of caspase-3 activity is defined as the amount of caspase-3 required to produce 1 pmol of pNA per minute at 25°C at saturating substrate concentration. For caspase-9 activity, acellular extracts were incubated with 20 M LEHD-AFC (Calbiochem, San Diego, Calif.) in a caspase assay buffer (100 mM HEPES, pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.05% bovine serum albumin, and 1 mM dithiothreitol) for 1 h at 37°C. AFC released from the substrates were excited at 400 nm. Emission was measured at 505 nm.
RESULTS
Overexpression of HSP27 induces resistance of U937 cells to VP-16
The U937 leukemic cell line was transfected with an insertless vector or an HSP27 containing vector. The control vector did not modify HSP27 expression as compared with the parental U937 cells (not shown). One control-transfected clone and two HSP27 overexpressing clones were selected for further analysis. HSP27 expression was about fivefold higher in the U937-27-4 and U937-27-7 clones than in the control-transfected clone (Fig. 1A) . Stable transfection of hsp27 did not affect the expression of other major heat shock proteins such as HSP70 or HSP90 (Fig.  1A) nor did it affect cell proliferation. The doubling time of control-transfected and HSP27-transfected clones was ϳ36 h. Overexpression of a functional HSP27 was confirmed by the 1.6-fold decrease in the basal cellular content of radical oxygen species (ROS) in hsp27-transfected compared to controltransfected cells (19, 25, 28) (Fig. 1B) . Cytotoxic and clonogenic survival assays have shown, in different cellular models, that HSP27 increases cell resistance to anticancer drugs (21, (23) (24) (25) 31) . By using a 96 h MTT assay, we consistently observed that overexpression of HSP27 protein decreased U937 cell sensitivity to etoposide-induced cytotoxicity. Etoposide IC 50 was ϳ0.69 M in the two hsp27-transfected clones as compared with 0.19 M in control transfected cells (Fig. 1C) . Since results obtained with the two selected HSP27-transfected clones (U937-27-7 and U937-27-4) were similar, results shown from subsequent experiments will be those obtained in the U937-27-4 clone.
HSP27 overexpression decreases etoposideinduced apoptosis in U937 cells
To determine the effect of HSP27 overexpression on apoptosis induction by etoposide treatment, hsp27-and control-transfected U937 cells were exposed to various concentrations of etoposide for 4 h. The number of apoptotic cells was assessed by counting apoptotic cells after Hoechst 33342 staining of the Immunoblot analysis of levels of HSP27, HSP70, and HSP90 in U937 cells transfected with either the insertless plasmid pcvK3 (control) or the human HSP27 cDNA containing plasmid (U937-27-4 and U937-27-7). One representative experiment is shown.B) In vivo estimation of intracellular ROS levels in U937 control-transfected (control) and hsp27-transfected cells (U937-27-4). As a positive control for ROS production, wild-type U937 cells were treated with 1 mM menadione for 10 min (menadione). Results are presented as mean oxidized HE (EB) fluorescence indexes, calculated by dividing the mean EB fluorescence of each sample by that measured in wild-type U937. sds are indicated (nϭ3).C) hsp27-transfected cells, U937-27-4 (F), and U937-27-7 (OE) as well as control-transfected cells (E) were treated with increasing concentrations of etoposide for 96 h. The y axis depicts the percent cell survival and the x axis depicts the concentration of etoposide (VP-16) used to treat cells. Data are illustrated as the mean Ϯ sds (nϭ4).
condensed nuclear chromatin (Fig. 2A) . The number of apoptotic cells measured was significantly reduced in hsp27-transfected compared with controltransfected cells. For example, at a dose of 50 M etoposide, overexpression of HSP27 caused a two-to threefold decrease in the number of apoptotic cells compared with that of control transfectants ( Fig.  2A) . These results were confirmed by monitoring the aberrant exposure of phosphatidylserine on the outer membrane leaflet as identified by the calciumdependent fixation of FITC-labeled annexin V (32) (data not shown). Hoechst 33342 staining was also used to assess apoptosis in hsp27-transfected U937 cells exposed for various times to 50 M etoposide (Fig. 2B) . In this experiment, we tested also bcl-2-transfected U937 cells to compare HSP27-mediated to Bcl-2-mediated antiapoptotic effects. After a 12 h exposure to the drug, more than 80% of the controltransfected cells were apoptotic. At this time point, the number of hsp27-and bcl-2-transfected cells that were apoptotic was ϳ40% and 25%, respectively. After 48 h of drug exposure, ϳ20% of HSP27 overexpressing cells remained nonapoptotic whereas all control cells were dead at 24 h After a 4-day drug exposure, virtually all the cells from control-, hsp27-, and bcl-2-transfected U937 cells had undergone apoptosis. We concluded that HSP27, like Bcl-2, delayed apoptosis induced by continuous exposure to 50 M etoposide in U937 cells.
To study the mechanism of action of HSP27 in a more physiological model system, we tested heatshocked U937 cells. Cells were studied after a 1 h heat shock at 42°C, followed by a 15 h incubation at 37°C. In these conditions, other main HSPs such as HSP70 and HSP90, which had been induced early by heat shock, had returned to their basal level whereas induction of HSP27 expression was maximal (Fig.  3A) . Apoptosis induced by a 4 h exposure to etoposide and measured by Hoechst 33342 staining was similarly reduced in both hsp27-transfected and heatshocked cells compared with control-transfected cells (Fig. 3B ).
HSP27 functions upstream of the activation of procaspase-2L, -3, -8, and -9.
We previously described the activation of procaspase-3 in etoposide-treated U937 cells, as demonstrated by the appearance of p19 and p17 fragments, and the cleavage of its 116 kDa protein target PARP into a 85 kDa fragment (5). These events were confirmed to occur in control-transfected U937 cells treated for 4 h with either 25 M or 50 M etoposide, whereas they were either undetectable or significantly decreased in HSP27-overexpressing U937 cells treated under similar conditions (Fig. 4) .
To better determine the mechanism by which HSP27 interferes with procaspase activation, we assessed the effect of etoposide on several other procaspases in control and hsp27-transfected cells. For this purpose, we analyzed by immunoblotting the expression of procaspase-8, procaspase-9, and the long isoform of procaspase-2 (procaspase-2L) in hsp27-and control-transfected U937 cells exposed to 50 M etoposide for 4 h (Fig. 5) . In control-transfected cells, this treatment decreased the content of the three procaspases studied, suggesting their cleavage into active subunits. Procaspase-9 proteolysis was confirmed by the appearance of a 37 kDa fragment in these cells. Overexpression of HSP27 inhibited procaspase-8 and procaspase-2L decrease and prevented procaspase-9 cleavage (Fig. 5) . Altogether, these observations indicated that HSP27 interfered with the activation of at least four procaspases: procaspase-2L, -3, -8, and 9. 
HSP27 overexpression does not prevent cytochrome c redistribution
Release of cytochrome c from the mitochondrial intermembrane space has been proposed as an early central event in the activation of procaspases by a variety of apoptotic stimuli (10, 33, 34) . This cytochrome c redistribution was shown to be prevented by the antiapoptotic protein Bcl-2 (34, 35). Accordingly, in etoposide-treated U937 cells, Bcl-2 overexpression completely inhibited cytochrome c redistribution from mitochondria to the cytosol (Fig. 6A) . By contrast, nearly all of the cytochrome c disappeared from the mitochondrial fraction and partitioned with the cytosolic (S100) fraction in both control-and hsp27-transfected cells treated in the same conditions (Fig. 6A) . These results suggested that HSP27 inhibited the activation of some procaspases downstream of the mitochondrial release of cytochrome c. To confirm these results, we followed cytochrome c release from the mitochondria in etoposide-treated cells by confocal microscopy. In untreated cells, cytochrome c demonstrated a con- fined localization (Fig. 6C ) similar to that observed with cytochrome oxidase (COX), another mitochondrial marker (Fig. 6B) . After etoposide treatment, HSP27-transfected cells demonstrated a diffuse pattern of cytochrome c staining (Fig. 6C ), similar to that observed when HSP27 was used as a cytosolic marker in control U937 cells (Fig. 6B) . By contrast, exposure of Bcl-2-transfected cells to etoposide did not modify cytochrome c staining (Fig. 6C) . Altogether, these results indicate that HSP27 interfered with etoposide-induced cell death downstream of the mitochondrial release of cytochrome c.
HSP27 overexpression inhibits cytochrome cinduced activation of procaspase-3
With the use of a cell-free system (30, 33) , it was shown that in the presence of dATP, cytochrome c could trigger the processing of procaspase-3 to active fragments in an untreated cell extract. This system was used to test the effect of HSP27 overexpression on cytochrome c-mediated activation of procaspase-3 in U937 cells. Horse heart cytochrome c and dATP (cytochrome c/dATP) were added to nuclei-and mitochondria-free cytosolic extracts (30) from either hsp27-, bcl-2-, or control-transfected U937 cells. After a 2 h incubation, procaspase-3 processing was analyzed by Western blot (Fig. 7A) and its activity was determined spectrophotometrically (Fig. 7B) . Cytochrome c/dATP induced procaspase-3 processing and caspase activation in cell-free extracts from control-and bcl-2-transfected U937 cells, but not in cell-free extracts from hsp27-transfected cells. To confirm that HSP27 was responsible for this effect, control U937 cell extracts were immunodepleted of HSP27. Immunodepletion resulted in a significant decrease in HSP27 content (Fig. 8A) and an increase in cytochrome c/dATP-induced caspase-3 activity (Fig. 8B ).
HSP27 overexpression inhibits cytochrome cinduced caspase-9 activity in cytochrome c/dATPtreated cell-free extracts
According to the current picture of the apoptotic pathway triggered by cytochrome c release from the mitochondria, caspase-9 activity is responsible for procaspase-3 activation by proteolytic cleavage. To determine whether caspase-9 activity was inhibited by HSP27 overexpression, we performed in vitro experiments using LEHD-AFC as a peptide substrate. LEHD-AFC substrate can be cleaved by caspase-4, -5, and -9 (36). It has been shown recently that procaspase-4 and -5 failed to be activated by cytochrome c/dATP in cell-free extracts (37) . Therefore, measurement of LEHD-AFC cleavage in such an in vitro system actually measured caspase-9 activity. We observed that in contrast to Bcl-2, HSP27 prevented LEHD cleavage induced by cytochrome c and dATP in this cell-free-system (Fig. 9A) . Immunodepletion of HSP27 from hsp27-transfected cell extracts partially restored the ability of cytochrome c/dATP to cleave LEHD-AFC substrate (Fig. 9B) . (50) . After 4 h, the cells were mechanically lysed and the mitochondrial and cytosolic (S100) fractions were analyzed by Western blot with an anti-human cytochrome c antibody. One representative of three immunoblots is shown. B) Confocal microscopy analysis of U937 cells labeled with an anti-cytochrome oxidase (COX Ab) and anti-human HSP27 (HSP27 Ab) antibodies as controls for mitochondrial and cytoplasmic localizations, respectively. C) Confocal microscopy analysis of cytochrome c distribution in untreated and etoposide-treated (VP-16, 50 M for 4 h) U937 cells stably transfected with hsp27 (U937-27-4) or bcl-2 (U937/Bcl-2). One representative of four independent experiments is shown.
DISCUSSION
Small stress proteins are part of the cellular mechanism that protects cells from the deleterious effects induced by heat or oxidative injuries (20 -22) . Among these proteins, HSP27 is an endogenous pleiotropic inhibitor of apoptotic cell death. We have previously shown HSP27's ability to block Fas/ APO-1-, tumor necrosis factor ␣-, and staurosporinemediated cell death in murine L929 fibroblasts (14) and prevent cisplatin-induced apoptosis in human colorectal cancer cells (25) . In the present study, HSP27 overexpression is shown to prevent etoposide-induced apoptosis and cytotoxicity by inhibiting cytochrome c and dATP-triggered caspase-9 activity in the cytosol of U937 leukemic cells.
The cleavage of intracellular proteins such as poly(ADP-ribose)polymerase, which is associated with apoptosis, is mediated by cysteine proteases from the caspase family (38) . We have previously demonstrated the central role of a DEVD-sensitive caspase in the proteolytic cascade that leads to PARP cleavage in etoposide-treated U937 cells (4, 5) . The main caspase that is sensitive to the tetrapeptide DEVD is caspase-3 (39) . This cytosolic protein normally exists as a 32 kDa inactive precursor that is cleaved proteolytically at aspartic residues in cells undergoing cell death to generate an active heterodimer of 17 kDa and 12 kDa subunits. The present study shows that HSP27 overexpression pre- vents the processing/activation of procaspase-3 and the subsequent cleavage of PARP in etoposidetreated U937 cells. In accordance with a recently described caspase cascade in which caspase-3 activates several downstream procaspases (37), HSP27 overexpression also prevented the activation of procaspase-2L and procaspase-8.
Several of the biochemical perturbations common to most apoptotic pathways result from alterations in mitochondrial functions, including the release of cytochrome c from intermembrane space (10, 33, 34, 40 -43) . The antiapoptotic proteins Bcl-2 and Bcl-X L have been shown to prevent mitochondrial physiology disruption and to block cytochrome c release from the mitochondria, whereas the proapoptotic protein Bax causes death by direct mitochondrial effects (35, 44, 45) . Here we show that in contrast to Bcl-2 and Bcl-2-related proteins, HSP27 overexpression does not influence the mitochondrial release of cytochrome c to the cytosol. Moreover, HSP27 overexpression does not prevent the early fall of the mitochondrial transmembrane potential (⌬ m ), as measured by the use of a cationic lipophilic fluorochrome (data not shown). According to the current picture of the common final pathway of apoptosis, these results suggest that HSP27 overexpression interferes with etoposide-induced death pathway between the mitochondrial release of cytochrome c and the activation of procaspase-3.
In the presence of cytochrome c and ATP or dATP, procaspase-9 combines with Apaf-1 to form a so-called 'apoptosome' (46) . In this complex, procaspase-9 is processed into an active caspase that, in turn, cleaves downstream caspases such as procaspase-3. In a cellfree system, procaspase-3 can be activated by the addition of cytochrome c and dATP to cytosol from normally growing cells (30, 33) . Here we show that whereas Bcl-2 overexpression fails to prevent procaspase-3 and procaspase-9 activation in this cell-free system, HSP27 overexpression blocks their processing into an active enzyme. Addition of commercially available recombinant HSP27 (rHSP27) to cell-free extracts failed to inhibit procaspase-3 activation induced by cytochrome c and dATP (data not shown). As the active forms of HSP27 with regard to inhibition of cell death are large nonphosphorylated oligomers (47, 48) , these negative results might be related to the inability of rHSP27 to form active oligomers. We used an antihuman HSP27 mAb and protein A-Sepharose to immunodeplete cell-free extracts of untreated cells from HSP27 protein. These experiments confirmed that HSP27 was responsible for the inhibition of cytochrome c/dATP-mediated procaspase-3 activation and caspase-9 activity. In a search for HSP27 interactions with any component of the apoptosome, we performed immunoprecipitation experiments. Although these studies failed to identify a strong interaction between the indicated proteins (data not shown), we cannot rule out the role of weaker or indirect interactions.
The differential effect of Bcl-2 and HSP27 on the activation of procaspases could be related to their subcellular distribution. Bcl-2 is localized mainly in the outer mitochondrial, outer nuclear, and endoplasmic reticular membranes as a result of a carboxy-terminal membrane anchor (43) whereas small stress proteins are dispersed in the cytosol (16) . As the presence of cytochrome c is required for the binding of Apaf-1 to procaspase-9, Bcl-2 must prevent the formation of the apoptosome and the activation of downstream caspases by inhibiting the mitochondrial release of cytochrome c. HSP27 overexpression does not prevent cytochrome c release from the mitochondria, but prevents the activation of procaspase-9 in etoposide treated cells and caspase-9 activity generated by cytochrome c and dATP in a cell-free system. Thus, HSP27 inhibits etoposideinduced U937 cell death between cytochrome c release from the mitochondrial intermembrane space and the activation of procaspase-9 in the apoptosome (Fig. 10) . It remains to be determined whether HSP27 could interact with either cytochrome c, procaspase-9, or other molecules that contribute to the formation of the apoptosome, such as APAF-1. Besides its role in the formation of apoptosome, cytochrome c was proposed to contribute to cell death by promoting free radical Figure 9 . HSP27 inhibits cytochrome c and dATP induced caspase-9 activity in HSP27-overexpressing U937 cell-free extracts. A) Equal amounts of cell-free extracts (500 g of total protein) from U937 cells transfected with either an insertless (control), a hsp27-containing (HSP27), or a bcl-2-containing (Bcl-2) vector were untreated or treated with 10 M cytochrome c and 1 mM dATP for 2 h at 37°C. Then caspase-9 activity was analyzed in cell lysates by measuring hydrolysis of the LEHD-AFC-specific peptide substrate. Results are expressed as percentage of the activity measured in control extracts. sds are indicated (nϭ3). B) Immunodepletion of HSP27 from U937 cell-free extracts increases cytochrome c/dATP-dependent caspase-9 activity. Cell-free extracts from HSP27-transfected cells were immunodepleted with a control IgG [IgG(Co)] or an antihuman HSP27 antibody (HSP27Ab), then treated with 10 M cytochrome c and 1 mM dATP for 2 h at 37°C. Caspase-9 activity was analyzed by measuring hydrolysis of LEHD-AFC substrate. Results are expressed as percentage of the activity measured in control extracts. sds are indicated (nϭ3). This signal induces the release of cytochrome c from the mitochondria. Overexpression of Bcl-2 prevents the release of cytochrome c from the mitochondria whereas HSP27 inhibits the activation of procaspase-9 by cytochrome c released in the cytosol, thereby inhibiting the activation of downstream procaspases such as procaspase-3.
